Skip to content

Effects of H1-Antagonist on Cognition

Effects of H1-Antagonist on Stages of Human Information Processing

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00846950
Enrollment
18
Registered
2009-02-19
Start date
2006-12-31
Completion date
2007-05-31
Last updated
2009-02-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cognition

Keywords

H1-antagonist, Event Related Potentials, Memory, Information processing, The effects of an H1 antagonist (dexchlorpheniramine) on human cognition

Brief summary

The purpose of this study is to determine whether histamine is involved in memory and specific processes in human cognition.

Detailed description

The neurotransmitter histamine appears to be involved in human cognitive performance. However, the exact role is very unclear. The role it plays in memory performance is highly disputed, as animal studies show decreased performance when the H1-receptor is blocked in the central nervous system while such findings in humans is scarce. To clarify the role of histamine in human memory and different processes in cognition, the effects of an H1-antagonist (dexchlorpheniramine) on memory, alertness and sensory and motor processes are measured. The study will be conducted according to a within subject cross-over design using healthy volunteers.

Interventions

DRUGdexchlorpheniramine, lorazepam

Sponsors

Maastricht University Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
Yes

Inclusion criteria

* Healthy as determined by a physician

Exclusion criteria

* present or history of any neurological of psychiatric disease * present or history of any substance abuse

Design outcomes

Primary

MeasureTime frame
P300 latency and LRP onset latency1.5 hours after treatment

Secondary

MeasureTime frame
Words recalled1.5 hours after treatment

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026